Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review

Donato Rigante, Jurgen Sota, Giuseppe Lopalco, Bruno Frediani, Rossella Franceschini, Mauro Galeazzi, Florenzo Iannone, Gian Marco Tosi, Claudia Fabiani, Luca Cantarini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

9 Citazioni (Scopus)

Abstract

Intraocular inflammation is one of the more relevant complications of Behçet's disease (BD), which tends to respond poorly to different medications. The ocular histopathologic changes are basically identical to those occurring in other organs and consist in a necrotizing leukocytoclastic obliterative vasculitis, which is probably immune complex-mediated and affects both arteries and veins of all sizes. There are growing evidences showing the potential role of biologic agents other than anti-tumor necrosis factor (TNF)-α agents in the management of ocular BD, which have been collected in this review, including interleukin-1 and interleukin-6 blockade, secukinumab, ustekinumab, daclizumab, rituximab, and alemtuzumab. Further large studies are needed to fully elucidate and establish the clinical efficacy of these different tools in the refractory ocular manifestations of BD.
Lingua originaleEnglish
pagine (da-a)1-10
Numero di pagine10
RivistaRheumatology International
Volume2017
DOI
Stato di pubblicazionePubblicato - 2017

Keywords

  • Behçet's disease
  • Uveitis

Fingerprint

Entra nei temi di ricerca di 'Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review'. Insieme formano una fingerprint unica.

Cita questo